Evidence map›Paper›PMID 34727912›Full record

ReviewBMC oral health2021

Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review.

Jinhan Zhou, Qinghua Mao, Yining Li, Zhiyong Li, Hong He, Qianming Chen, Chuanxia Liu

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in BMC oral health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jinhan ZhouStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Qinghua MaoStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Yining LiStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Zhiyong LiStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Hong HeStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Qianming ChenStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China.
Chuanxia LiuStomatology Hospital, School of Stomatology, Zhejiang University School of Medcine, Zhejiang Province Clinical Research Center for Oral Diseases, Key Laboratory of Oral Biomedical Rsearch of Zhejiang Province, Cancer Center of Zhejiang University, Hangzhou, 310006, China. 0014806@zju.edu.cn.ORCID 0000-0002-7484-2310
Stomatology Hospital · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntibodies to PD-1 and PD-L1 have remarkably improved the overall survival of many patients with advanced solid tumors. SHR-1210 is an anti-PD-1 monoclonal antibody. Dermatologic reactive capillary hemangiomas (RCH) were the most common and unique drug-related AEs of SHR-1210, but rare on oral mucosa and gastrointestinal mucosa. Herein we report a case of RCH occurred in oral mucosa during the clinical trials of SHR-1210 in the treatment of non-small cell lung cancer. CASE PRESENTATION: A male in his 60 s with a history of non-small cell lung cancer received injection of anti-PD-1 monoclonal antibodies SHR-1210. The patient developed drug-related RCH on skin after the first injection and began to have gingival hyperplasia one year after the first injection which gradually increased in size and affect eating and speaking. Anti-PD-1 treatments were continued. After periodontal treatment, two oral lesions and one skin lesion were surgically removed. Similar histological manifestation was found in all three lesions as reactive capillary hemangiomas. All lesions had a good prognosis without recurrence on oral mucosa within one year after surgery.

conclusionsOral reactive capillary hemangiomas could be induced by SHR-1210 in the treatment of non-small cell lung cancer. Surgical resection is an effective treatment with a good prognosis.

Indexed as

Carcinoma, Non-Small-Cell LungHemangioma, CapillaryLung NeoplasmsAntibodies, Monoclonal, HumanizedHumansMaleAntibodies, Monoclonal, HumanizedcamrelizumabAnti-PD-1 antibodyCase reportNon-small cell lung cancerOralReactive capillary hemangiomas

Identifiers

PMID34727912
PMCPMC8561900
OpenAlexW3208514216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.